Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Tabletop particle accelerator could transform medicine and materials science 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
